Professional
Added to YB: 2023-12-12
Pitch date: 2023-12-12
CRSP [bullish]
CRISPR Therapeutics AG
-5.3%
current return
Author Info
No bio for this author
Company Info
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
Market Cap
$5.1B
Pitch Price
$57.70
Price Target
119.00 (+118%)
Dividend
N/A
EV/EBITDA
-6.57
P/E
-8.27
EV/Sales
959.56
Sector
Biotechnology
Category
special_situation
CRISPR Therapeutics: FDA Approves Gene Editing Drug for Sickle Cell Disease; Positive Long-Term Outlook
$CRSP $VRTX: FDA approved Casgevy, 1st CRISPR-based drug for sickle cell. $2.2M price vs $3.1M for $BLUE's Lyfgenia (with black box warning). Expect strong uptake of safer, cheaper Casgevy. Maintain FVEs of $119 for CRSP, $314 for VRTX. CRSP undervalued, risky; VRTX fairly valued.
Read full article (11 min)